SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bitnum S, Daeschner C Jr, Travis LB, Dodge WF, Hopps HC. Dermatomyositis. J Pediatr 1964; 64: 10131.
  • 2
    Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria R, Malleson P, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2001; 43: 5419.
  • 3
    Stringer E, Ota S, Bohnsack J, Bowyer SL, Lindsley CB, Griffin TA, et al. Diversity of treatment approaches to juvenile dermatomyositis across North America: the Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM treatment survey [abstract]. Arthritis Rheum 2008; 58 Suppl: S255.
  • 4
    Horton J. Nominal group technique: a method of decision-making by committee. Anaesthesia 1980; 35: 8114.
  • 5
    Ruperto N, Ravelli A, Murray K, Lovell DJ, Andersson-Gare B, Feldman BM, et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford) 2003; 42: 14529.
  • 6
    Miller FM, Rider LG, Chung Y, Cooper R, Danko K, Farewell V, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathy. Rheumatology (Oxford) 2001; 40: 126273.
  • 7
    Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer SL, Dyer A, et al, for the NIAMS Juvenile DM Registry Physician Referral Group. US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003; 49: 3005.
  • 8
    Lovell DJ, Lindsley CB, Rennebohm RM, Ballinger SH, Bowyer SL, Giannini EH, et al, and the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum 1999; 42: 22139.
  • 9
    Huber AM, Feldman BM, Rennebohm RM, Hicks JE, Lindsley CB, Perez MD, et al, for the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2004; 50: 1595603.
  • 10
    Jain M, Smith M, Cintas H, Koziol D, Wesley R, Harris-Love M, et al. Intra-rater and inter-rater reliability of the 10-point manual muscle test (MMT) of strength in children with juvenile idiopathic inflammatory myopathies (JIIM). Phys Occup Ther Pediatr 2006; 26: 517.
  • 11
    Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, et al. The Cutaneous Assessment Tool (CAT): development and reliability in juvenile idiopathic inflammatory myopathy. Rheumatology (Oxford) 2007; 46: 160611.
  • 12
    Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, et al, and the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. Arthritis Rheum 2008; 59: 21421.
  • 13
    Ruperto N, Ravelli A, Pistorio A, Ferriani V, Calvo I, Ganser G, et al, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Paediatric Rheumatology Collaborative Study Group (PRCSG). The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 2008; 59: 413.
  • 14
    Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum 2003; 49: 715.
  • 15
    Rider LG, Feldman BM, Perez MD, Rennebohm RM, Lindsley CB, Zemel LS, et al, and the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. I. Physician, parent, and patient global assessments. Arthritis Rheum 1997; 40: 197683.
  • 16
    Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, et al. Defining clinical improvement in adult and juvenile myositis. J Rheumatol 2003; 30: 60317.
  • 17
    Seshadri R, Feldman BM, Ilowite N, Cawkwell G, Pachman LM. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum 2008; 59: 98995.
  • 18
    Pullenayequm E, Lam C, Manlhiot C, Feldman BM. Fitting marginal structural models: estimating covariate-treatment associations in the reweighted data set can guide model fitting. J Clin Epidemiol 2008; 61: 87581.